Premium
Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model
Author(s) -
Frazier J. P.,
Beirne E.,
Ditzler S. H.,
Tretyak I.,
Casalini J. R.,
Thirstrup D. J.,
Knoblaugh S.,
Ward J. G.,
Tripp C. D.,
Klinghoffer R. A.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12215
Subject(s) - docetaxel , gemcitabine , doxorubicin , medicine , soft tissue sarcoma , sarcoma , immunohistochemistry , pathology , cancer research , oncology , cancer , chemotherapy
Abstract Spontaneously occurring soft tissue sarcoma ( STS ) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STS s are a valuable and readily available resource for the study of new therapeutics. In this study, a canine patient‐derived xenograft ( PDX ) model, CDX‐STS2 , was established. The CDX‐STS2 model was engrafted and expanded for systemic administration studies with chemotherapeutic agents commonly used to treat STS , including doxorubicin, docetaxel and gemcitabine. Immunohistochemistry for drug‐specific biomarkers and tumour growth measurement revealed tumour sensitivity to doxorubicin and docetaxel, whereas gemcitabine had no effect on tumour growth. Although many human PDX tumour models have been established, relatively few canine PDX models have been reported to date. CDX‐STS2 represents a new STS PDX research model of canine origin that will be useful in bridging preclinical research with clinical studies of STS in pet dogs.